Of note, downregulation of the well-established histological marker of SS, the prosurvival BCL2 protein (Barrott et al., 2017; Fairchild et al., 2021; Hirakawa et al., 1996), was also observed following TAK-981 treatment, without changes in other BCL2 family member proteins (Fig. 1G and S2C). The gene discussed is BCL2; the disease is synovial sarcoma.